Article
Gastroenterology & Hepatology
Suqing Li, Marc Monachese, Misbah Salim, Naveen Arya, Anand Sahai, Nauzer Forbes, Christopher Teshima, Mohammad Yaghoobi, Yen- Chen, Eric Lam, Paul James
Summary: This study proposes standard EUS reporting elements to improve patient care during EUS procedures, including preprocedural, intraprocedural, and postprocedural components. Standardizing reporting elements may help ensure ongoing best practices and quality improvement in EUS.
ENDOSCOPIC ULTRASOUND
(2021)
Article
Clinical Neurology
Bruno Dubois, Nicolas Villain, Giovanni B. Frisoni, Gil D. Rabinovici, Marwan Sabbagh, Stefano Cappa, Alexandre Bejanin, Stephanie Bombois, Stephane Epelbaum, Marc Teichmann, Marie-Odile Habert, Agneta Nordberg, Kaj Blennow, Douglas Galasko, Yaakov Stern, Christopher C. Rowe, Stephen Salloway, Lon S. Schneider, Jeffrey L. Cummings, Howard H. Feldman
Summary: The use of biomarkers in the diagnosis of Alzheimer's disease has limitations and should be used cautiously in a clinical setting, restricted to individuals with specific phenotypes and positive biomarkers. Biomarker-positive cognitively unimpaired individuals should be considered at-risk for progression to Alzheimer's disease.
Review
Oncology
Evangelos Terpos, Elena Zamagni, Suzanne Lentzsch, Matthew T. Drake, Ramon Garcia-Sanz, Niels Abildgaard, Ioannis Ntanasis-Stathopoulos, Fredrik Schjesvold, Javier de la Rubia, Charalampia Kyriakou, Jens Hillengass, Sonja Zweegman, Michele Cavo, Philippe Moreau, Jesus San-Miguel, Meletios A. Dimopoulos, Nikhil Munshi, Brian G. M. Durie, Noopur Raje
Summary: The Bone Working Group of the International Myeloma Working Group recommends the use of zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma. Denosumab can be considered for patients with renal impairment. Cement augmentation is effective for painful vertebral compression fractures.
Article
Medical Laboratory Technology
Gabor Cserni, Edi Brogi, Hiram S. Cody, Rahul Deb, Gelareh Farshid, Sandra O'Toole, Elena Provenzano, Cecily M. Quinn, Aysegul A. Sahin, Fernando Schmitt, Donald L. Weaver, Rin Yamaguchi, Fleur Webster, Puay Hoon Tan
Summary: The International Collaboration on Cancer Reporting (ICCR) has published a data set for the reporting of surgically removed lymph nodes in breast cancer, aiming to standardize lymph node evaluation and improve patient outcomes.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Review
Oncology
Claire Piccinin, Ethan Basch, Vishal Bhatnagar, Melanie Calvert, Alicyn Campbell, David Cella, Charles S. Cleeland, Corneel Coens, Anne -Sophie Darlington, Amylou C. Dueck, Mogens Groenvold, Ralf Herold, Bellinda L. King-Kallimanis, Paul G. Kluetz, Dagmara Kulis, Daniel O'Connor, Kathy Oliver, Madeline Pe, Bryce B. Reeve, Jaap C. Reijneveld, Xin Shelley Wang, Andrew Bottomley
Summary: The use of item libraries in oncology trials allows for customised patient-reported outcome (PRO) measurement that aligns with the needs of the target population and intervention. However, there is a lack of guidance on how to design and implement these customised PRO measures across different measurement systems. To address this gap, an international working group was formed to develop recommendations for the use of item libraries in oncology trials. The resulting recommendations provide guidance on item selection, structure and analysis of item lists, and their integration with other measures.
Review
Oncology
Philippe Moreau, Shaji K. Kumar, Jesus San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian G. M. Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele Cavo, Sigurdur Y. Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C. Anderson, Cristina Joao, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G. Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Blade, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf-Henrik Mellqvist, Dominik Dytfeld, Jean-Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksac, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria-Victoria Mateos, S. Vincent Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson
Summary: This policy review presents clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma, integrating drug access issues for patients in different income settings to improve patient outcomes in real-world practice.
Article
Radiology, Nuclear Medicine & Medical Imaging
Riad Salem, Siddharth A. Padia, Marnix Lam, Carlo Chiesa, Paul Haste, Bruno Sangro, Beau Toskich, Kirk Fowers, Joseph M. Herman, S. Cheenu Kappadath, Thomas Leung, Daniel Y. Sze, Edward Kim, Etienne Garin
Summary: This article presents the updated recommendations from the TheraSphere Global Dosimetry Steering Committee for the treatment of hepatocellular carcinoma (HCC). The recommendations aim to provide a more personalized and effective approach to treatment, taking into account disease presentation, tumor biology, and treatment intent.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Medical Laboratory Technology
Sunati Sahoo, Gregor Krings, Yunn-Yi Chen, Jodi M. Carter, Beiyun Chen, Hua Guo, Hanina Hibshoosh, Emily Reisenbichler, Fang Fan, Shi Wei, Laila Khazai, Ronald Balassanian, Molly E. Klein, Sonal Shad, Sara J. Venters, Alexander D. Borowsky, Fraser Symmans, I. Tolgay Ocal
Summary: Neoadjuvant systemic therapy is commonly used before surgical treatment for breast cancer, leading to routine evaluation of treated breast carcinomas in pathology practices. However, there is no universally adopted protocol for evaluating and reporting these specimens. The Residual Cancer Burden system, which quantifies treatment response using residual tumor burden, is currently the only web-based system available.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2023)
Review
Cell Biology
Gordan M. Vujanic, Ellen D'Hooghe, Christian Vokuhl, Paola Collini
Summary: ICCR develops datasets for histopathological reporting of various cancer types, but international reporting guidelines for Wilms' tumors have not been established yet. Different treatment approaches result in varied assessment methods and classification criteria followed by countries worldwide.
Article
Pathology
Alfred K. Lam, Michael J. Bourke, Renyin Chen, Roberto Fiocca, Fumiyoshi Fujishima, Satoshi Fujii, Marnix Jansen, Priyanthi Kumarasinghe, Rupert Langer, Simon Law, Sybren L. Meijer, Cian Muldoon, Marco Novelli, Chanjuan Shi, Laura Tang, Iris D. Nagtegaal
Summary: The article introduces the standardized data set for esophageal carcinoma pathology reporting developed based on the ICCR approach, aiming to improve cancer patient outcomes and international benchmarking in cancer management. The data set includes clinical and pathological parameters, with core elements covering various aspects of the tumor, and non-core elements providing additional detailed information.
Article
Pathology
Deepti Dhall, Jiaqi Shi, Daniela S. Allende, Kee-Taek Jang, Olca Basturk, Volkan Adsay, Grace E. Kim
Summary: The study highlighted discrepancies in the definition of margins and documentation practices for pancreatic ductal adenocarcinoma, although some consensus was reached on certain key points.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Review
Medical Laboratory Technology
Anna Porwit, Marie C. Bene, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel, Theresia M. Westers, Orianne Wagner-Ballon, Shahram Kordasti, Peter Valent, Frank Preijers, Canan Alhan, Frauke Bellos, Peter Bettelheim, Kate Burbury, Nicolas Chapuis, Eline Cremers, Matteo G. Della Porta, Alan Dunlop, Lisa Eidenschink-Brodersen, Patricia Font, Michaela Fontenay, Willemijn Hobo, Robin Ireland, Ulrika Johansson, Michael R. Loken, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Leonie Saft, Dolores Subira, Jeroen te Marvelde, Denise A. Wells, Vincent H. J. van der Velden, Wolfgang Kern, Arjan A. van de Loosdrecht
Summary: Multiparameter flow cytometry (MFC) is an essential method in bone marrow investigation for patients with cytopenia and suspected myelodysplastic syndrome (MDS), providing valuable information for diagnosis and treatment follow-up. This document summarizes recommendations from the ELN iMDS Flow on analytical issues in MFC, including the analysis of different cell subsets and the use of specific markers for MDS diagnosis. Machine-learning-based analytical tools and large uniform datasets are suggested for future research to improve integrated diagnostics and risk stratification in MDS.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Genetics & Heredity
Melyssa Aronson, Chrystelle Colas, Andrew Shuen, Heather Hampel, William D. Foulkes, Hagit Baris Feldman, Yael Goldberg, Martine Muleris, Kami Wolfe Schneider, Rose B. McGee, Kory Jasperson, Arun Rangaswami, Laurence Brugieres, Uri Tabori
Summary: CMMRD is the most aggressive cancer predisposition syndrome associated with multiorgan cancers, often presenting in childhood. A multidisciplinary international working group established seven diagnostic criteria for the diagnosis of CMMRD, including definitive and likely diagnostic criteria. The criteria incorporate genetic testing, ancillary tests, and clinical manifestations to determine a diagnosis, with a focus on appropriate surveillance and treatment for improved survival.
JOURNAL OF MEDICAL GENETICS
(2022)
Article
Dermatology
E. A. Olsen, M. Harries, A. Tosti, W. Bergfeld, U. Blume-Peytavi, V. Callender, V. Chasapi, O. Correia, G. Cotsarelis, R. Dhurat, N. Dlova, I. Doche, N. Enechukwu, R. Grimalt, S. Itami, M. Hordinsky, K. Khobzei, W. -S. Lee, S. Malakar, A. Messenger, A. McMichael, P. Mirmirani, Y. Ovcharenko, S. Papanikou, G. M. Pinto, B. M. Piraccini, R. Pirmez, P. Reygagne, J. Roberts, L. Rudnicka, D. Saceda-Corralo, J. Shapiro, T. Silyuk, R. Sinclair, R. O. Soares, A. Souissi, A. Vogt, K. Washenik, A. Zlotogorski, D. Canfield, S. Vano-Galvan
Summary: A group of international experts in hair loss established consensus recommendations for clinical trials on Frontal Fibrosing Alopecia (FFA), including standardized diagnostic criteria, severity rating, staging, and assessment methods. These guidelines aim to facilitate the collection of reliable data on FFA and advance research efforts to address knowledge gaps in this condition.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Review
Psychology, Developmental
Cathy Creswell, Maaike H. Nauta, Jennifer L. Hudson, Sonja March, Tessa Reardon, Kristian Arendt, Denise Bodden, Vanessa E. Cobham, Caroline Donovan, Brynjar Halldorsson, Tina In-Albon, Shin-Ichi Ishikawa, Daniel Bach Johnsen, Maral Jolstedt, Rachel de Jong, Leonie Kreuze, Lynn Mobach, Ronald M. Rapee, Susan H. Spence, Mikael Thastum, Elisabeth Utens, Sarah Vigerland, Gro Janne Wergeland, Cecilia A. Essau, Anne Marie Albano, Brian Chu, Muniya Khanna, Wendy K. Silverman, Philip C. Kendall
Summary: Anxiety disorders in children and young people are common and have significant personal and societal costs. Research on treatments for these disorders has increased, leading to challenges in comparing studies due to variations in outcome measures and reporting methods. Recommendations have been made to improve international consistency in trial reporting and to take full advantage of data sharing opportunities.
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY
(2021)
Article
Oncology
Heather J. Bax, Jitesh Chauhan, Chara Stavraka, Aida Santaolalla, Gabriel Osborn, Atousa Khiabany, Melanie Grandits, Jacobo Lopez-Abente, Lais C. G. F. Palhares, Charleen Chan Wah Hak, Alexandra Robinson, Amy Pope, Natalie Woodman, Cristina Naceur-Lombardelli, Sadek Malas, Jack E. M. Coumbe, Mano Nakamura, Roman Laddach, Silvia Mele, Silvia Crescioli, Anna M. Black, Sara Lombardi, Silvana Canevari, Mariangela Figini, Ahmad Sayasneh, Sophia Tsoka, Kevin FitzGerald, Cheryl Gillett, Sarah Pinder, Mieke Van Hemelrijck, Rebecca Kristeleit, Sharmistha Ghosh, Ana Montes, James Spicer, Sophia N. Karagiannis, Debra H. Josephs
Summary: This study investigated the potential use of sFR alpha as a biomarker for ovarian cancer. The results showed that sFR alpha levels were significantly higher in patients compared to healthy volunteers and decreased alongside tumor burden during treatment. Additionally, high concentrations of sFR alpha reduced the effectiveness of anti-FR alpha antibodies, but this effect could be overcome by increasing antibody doses.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Chiara Corti, Marisa Cobanaj, Edward C. Dee, Carmen Criscitiello, Sara M. Tolaney, Leo A. Celi, Giuseppe Curigliano
Summary: Artificial intelligence (AI) has grown explosively in the field of oncology and related specialties. The advancements in data capture and analysis, along with decreasing costs of genome sequencing, provide valuable tools for biomedical research and cancer care. However, there are technical challenges and biases to address in AI implementation in medicine. A thoughtful and inclusive approach is crucial to avoid exacerbating existing health disparities.
CANCER TREATMENT REVIEWS
(2023)
Article
Computer Science, Interdisciplinary Applications
Celestin Bigarre, Francois Bertucci, Pascal Finetti, Gaetan Macgrogan, Xavier Muracciole, Sebastien Benzekry
Summary: This study proposes a novel mathematical model to predict the risk of metastatic relapse in early-stage breast cancer patients. By using mixed-effects modeling, the researchers identified two mathematical parameters representing growth and dissemination abilities. They found that Ki67 and Thymidine Kinase-1 were associated with growth, while nodal status and Plasminogen Activator Inhibitor-1 were associated with dissemination.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
(2023)
Article
Oncology
Matteo Repetto, Edoardo Crimini, Luca Boscolo Bielo, Elena Guerini-Rocco, Liliana Ascione, Andrea Bonfanti, Cristina Zanzottera, Luca Mazzarella, Alberto Ranghiero, Carmen Belli, Carmen Criscitiello, Angela Esposito, Massimo C. P. Barberis, Giuseppe Curigliano
Summary: Precision oncology aims to improve clinical outcomes by personalizing treatment options for cancer patients. Utilizing ESCAT allows evidence-based evaluation of genomic findings for treatment selection. Molecular tumor boards provide the multidisciplinary expertise necessary for ESCAT evaluation and strategic treatment choice.
EUROPEAN JOURNAL OF CANCER
(2023)
Letter
Oncology
Paolo Tarantino, Eleonora Nicolo, Giuseppe Curigliano
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Federica Giugliano, Giuseppe Curigliano, Paolo Tarantino
Summary: HER2-low breast cancers, traditionally considered insensitive to HER2-targeting agents, have shown sensitivity to antibody-drug conjugates (ADCs). Clinical trials have demonstrated the effectiveness of trastuzumab deruxtecan and sacituzumab govitecan in treating HER2-low breast cancer, reshaping treatment approaches for this disease.
EUROPEAN JOURNAL OF CANCER PREVENTION
(2023)
Article
Oncology
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes
Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.
Article
Oncology
Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Summary: This study explored the predictive ability of DNA damage response (DDR) and immune markers in the treatment response of triple-negative breast cancer. High immune features predict response to docetaxel, while high DDR signature scores predict response to carboplatin. Patients can be divided into different subgroups based on their treatment sensitivity. Caution is needed when using transcriptional signatures derived from primary tumors to guide treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. J. Veal, Christopher J. J. Corrigan, Stephen J. J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. J. Bax, Debra H. H. Josephs, Sophia N. N. Karagiannis
Summary: The study reports the results of a phase I dose escalation trial of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing folate receptor-alpha. The most common toxicity observed was transient urticaria and evidence of anti-tumour activity was observed in a patient with ovarian cancer.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
D. G. J. Linders, M. M. Deken, M. A. van Dam, M. N. J. M. Wasser, E. M. C. Voormolen, J. R. Kroep, G. A. M. S. van Dongen, D. Vugts, H. M. Oosterkamp, M. E. Straver, C. J. H. van de Velde, D. Cohen, P. Dibbets-Schneider, F. H. P. van Velden, L. M. Pereira Arias-Bouda, A. L. Vahrmeijer, G. J. Liefers, L. F. de Geus-Oei, D. E. Hilling
Summary: Accurate assessment of neoadjuvant therapy (NAT) response in HER2-positive breast cancer remains challenging. This study investigated the feasibility of using HER2-targeted PET/CT imaging for more accurate NAT response evaluation. The results showed that qualitative assessment of the PET/CT images was not superior to standard-of-care MRI, but quantitative assessment suggested that HER2-targeted PET/CT has potential for a more accurate response evaluation of the primary tumor after NAT in HER2-positive breast cancer.
Letter
Medicine, General & Internal
Sara A. Hurvitz, Giuseppe Curigliano, Anton Egorov, Shahid Ashfaque, Javier Cortes
Review
Oncology
Carmine Valenza, Graziella Rizzo, Maria Ilenia Passalacqua, Laura Boldrini, Chiara Corti, Dario Trapani, Giuseppe Curigliano
Summary: Immune checkpoint inhibitors have had a significant impact on the treatment of breast cancer, especially in the case of triple-negative breast cancer. Current research aims to improve upon these results by exploring novel combinations and strategies, investigating the role of ICIs beyond TNBC, and better selecting patients for treatment. This narrative review provides a summary of the evolving landscape of immunotherapeutic treatments for breast cancer, highlighting current challenges and future perspectives.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Oncology
Carmine Valenza, Beatrice Taurelli Salimbeni, Celeste Santoro, Dario Trapani, Gabriele Antonarelli, Giuseppe Curigliano
Summary: Tumor-infiltrating lymphocytes (TILs) are a potential biomarker with prognostic and predictive potential in breast cancer. They have been shown to have higher treatment response and improved survival outcomes in early triple-negative breast cancer. However, the clinical use of TILs as biomarkers is limited by the lack of rigorous validation. This review discusses the current issues and future challenges in assessing and validating TILs as predictive and prognostic biomarkers in breast cancer.
Review
Oncology
Eleonora Nicolo, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino
Summary: HER2-low expression is an essential biomarker for treatment selection in breast cancer, and recent clinical trials have shown promising results with novel HER2-targeted therapies. It is important to develop more sensitive and reliable methods for HER2 testing and scoring to accurately identify patients who may benefit from these treatments.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Pathology
Juliana Mota Siqueira, Yoshitsugu Mitani, Camilla Oliveira Hoff, Flavia Bonini, Luana Guimaraes de Sousa, Mario L. Marques-Piubelli, Anurag Purushothaman, Mutsumi Mitani, Hui Dai, Shiaw-Yih Lin, Michael T. Spiotto, Ehab Y. Hanna, Daniel J. McGrail, Adel K. El-Naggar, Renata Ferrarotto
Summary: B7-H4 expression pattern varies among different types of salivary gland carcinomas, and high B7-H4 expression is associated with poor prognosis in adenoid cystic carcinoma.
Article
Pathology
Basile Tessier-Cloutier, Felix K. F. Kommoss, David L. Kolin, Kristyna Nemejcova, Dupreez Smith, Jennifer Pors, Colin J. R. Stewart, W. Glenn Mccluggage, William D. Foulkes, Andreas von Deimling, Martin Kobel, Cheng-Han Lee
Summary: This study provides a detailed analysis of the clinical, pathological, immunohistochemical, and molecular features of DDOC/UDOC. The majority of patients presented with extraovarian disease and had rapid disease progression resulting in high mortality rate.
Review
Pathology
Sophia J. Wagner, Christian Matek, Sayedali Shetab Boushehri, Melanie Boxberg, Lorenz Lamm, Ario Sada, Dominik J. E. Winter, Carsten Marr, Tingying Peng
Summary: Computational pathology research driven by deep learning faces challenges in reproducibility and reusability. Codebase with good documentation and robustness and generalizability of models are crucial. The reuse of computational pathology algorithms is limited, and their application in clinical settings is even rarer. This study evaluates 160 peer-reviewed articles, providing criteria for data and code availability and statistical analysis of results.
Article
Pathology
Andres M. Acosta, Lynette M. Sholl, Fiona Maclean, Chia-Sui Kao, Thomas M. Ulbright
Summary: This study assessed the clinicopathologic and genomic features of 14 cases of testicular sex cord-stromal tumors. The results showed that CTNNB1 mutations are rare in these tumors, and most of them have genomic alterations similar to testicular sex cord-stromal tumors with pure or predominant spindle cell components.
Article
Pathology
Toru Odate, Kaishi Satomi, Takashi Kubo, Yuko Matsushita, Toshihide Ueno, Akira Kurose, Kohei Shomori, Tokiko Nakai, Reiko Watanabe, Keiko Segawa, Shusa Ohshika, Naritomo Miyake, Sayaka Kudo, Tatsunori Shimoi, Eisuke Kobayashi, Motokiyo Komiyama, Seiichi Yoshimoto, Fumihiko Nakatani, Akira Kawai, Yasushi Yatabe, Shinji Kohsaka, Koichi Ichimura, Hitoshi Ichikawa, Akihiko Yoshida
Summary: Inflammatory rhabdomyoblastic tumors (IRMTs) are newly recognized skeletal muscle tumors with uncertain malignant potential. This study investigated 13 IRMTs using clinicopathologic, genetic, and epigenetic methods. The results showed specific histologic features and genetic mutations in these tumors, and most of them exhibited benign behavior.
Article
Pathology
Dale L. Davis, Adam C. Lechner, David B. Chapel, Jonathan C. Slack, Chrystalle Katte Carreon, Bradley J. Quade, Carlos Parra-Herran
Summary: The Amsterdam Consensus Statement introduced the term maternal vascular malperfusion (MVM) to classify a group of findings related to impaired maternal-placental circulation. The study found that features such as low placental weight, accelerated villous maturation, decidual arteriopathy, and infarcts are associated with adverse obstetrical outcomes, while the role of other features like distal villous hypoplasia, excess multinucleated trophoblast, and retroplacental hemorrhage needs further research.
Review
Pathology
Alain C. Borczuk
Summary: COVID-19 is an acute respiratory illness that can progress to acute respiratory distress syndrome. While most patients recover completely, some may experience persistent respiratory dysfunction, known as long COVID. The pathogenesis involves immune and cellular disturbances.
Article
Pathology
Annikka Weissferdt, Cheuk H. Leung, Heather Lin, Boris Sepesi, William N. William, Stephen G. Swisher, Tina Cascone, J. Jack Lee, Abujiang Pataer
Summary: Neoadjuvant treatment of non-small cell lung cancer challenges traditional processing of pathology specimens, and accurate evaluation of residual tumor is crucial for assessing treatment efficacy.